[Acute phase reaction following bisphosphonates.]

Area of Science:

• Pharmacology
• Immunology
• Bone Biology

Background:

• Bisphosphonates are crucial for reducing bone resorption, fragility fractures, and bone metastasis pain.
• Initial doses of aminobisphosphonates can trigger an acute phase response (APR), characterized by flu-like symptoms due to inflammatory cytokine release.
• Nitrogen-containing bisphosphonates (N-BPs) inhibit osteoclast function by targeting farnesyl diphosphate (FPP) synthase.

Purpose of the Study:

• To investigate the mechanisms behind the acute phase response (APR) following bisphosphonate administration.
• To explore strategies for mitigating the severity of APR.
• To assess the impact of APR on long-term patient adherence to bisphosphonate therapy.

Main Methods:

• The study reviews the mechanism of N-BP action, including their interaction with the mevalonate pathway and immune cells.
• It examines trial evidence on the efficacy of acetaminophen in reducing APR severity.
• Correlation between 25(OH)D levels and APR incidence/severity was analyzed.

Main Results:

• N-BP uptake by monocytes leads to intracellular isopentenyl diphosphate (IPP) accumulation, activating γδT cells and releasing pro-inflammatory cytokines, causing APR.
• Acetaminophen coadministration can reduce APR severity by over half, making it advisable for initial N-BP dosing.
• Lower 25(OH)D levels correlate with higher APR incidence and severity; Vitamin D may reduce musculoskeletal pain post-dosing.

Conclusions:

• Understanding the mechanism of APR is key to managing bisphosphonate therapy.
• Acetaminophen and Vitamin D are potential strategies to alleviate APR symptoms and improve patient experience.
• APR has minimal long-term impact on adherence, but patient education prior to administration is important.